Pharmaniaga officially exited PN17 status in March, having taken three years to complete its regularisation plan. The firm is now vying to become the most valuable pharmaceutical company in Malaysia by 2030 leveraging on its ongoing government concession in logistics and biopharma manufacturing capabilities. We catch-up with Managing Director Dato’ Zulkifli Jafar to find out how he intends to achieve this goal.

Khairy Jamaluddin: Back in the Running
34:25

Caught in the Chip War: Perspectives from the Netherlands
25:36

Gulf War: Navigating A Multi-Wave Crisis
32:33